ClinicalTrials.gg
CompletedNCT00090259Updated May 16, 2024Results posted

Study to Evaluate Potential Decrease in Hospitalization Events, Time Between Events, and Increasing Longevity in Patients With Symptomatic Heart Failure (0954-948)

A Phase 3 interventional study of Losartan 50 mg and Losartan 150 mg in Heart Failure, sponsored by Organon and Co. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-16.

Sponsored by Organon and Co · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 8 months after the study started (first participant enrolled Dec 2001, registered Aug 2004).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
3,834
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a multicenter study to evaluate potential decrease in hospitalization events and time between events and increasing longevity in patients with symptomatic congestive heart failure and intolerant of first-line medication for heart failure. This study will evaluate if higher doses of the investigational drug given daily will be superior to the lower dose of the same investigational drug given daily.

02

Conditions studied

  • Heart Failure

Browse trials for

03

In context

Heart Failure

6,334 studies on the registry are indexed under Heart Failure; 1,394 are open to participants now.

This study's enrollment of 3,834 is above the median of 76 across 4,049 interventional studies indexed under Heart Failure.

Browse Heart Failure studies →

Lead sponsor

Organon and Co is the lead sponsor of 505 studies on the registry; none are open to participants now.

Of its 23 completed or terminated interventional studies of FDA-regulated products, 18 (78%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Symptomatic heart failure with known or recently diagnosed intolerance of treatment with medication for heart failure
  • May or may not be receiving an alternative and/or additional drug treatment
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
3,834 participants (actual)

Study arms

  • Experimental
    Losartan 50 mg

    50-mg losartan tablet administered daily with 1 tablet of 100-mg losartan placebo beginning Week 1 and continuing to end of study (up to 4 years)

    Drug: Losartan 50 mg

  • Experimental
    Losartan 150 mg

    Titrated losartan administration up to daily 150-mg losartan: Week 1, daily 50-mg losartan tablet coadministered with 100-mg losartan placebo; Week 2, daily 50-mg losartan placebo coadministered with 100-mg losartan; Week 3 to end of study (up to 4 years), daily 50-mg losartan tablet coadministered with 100-mg losartan

    Drug: Losartan 150 mg

Interventions

  • 50-mg losartan oral tablet

    Also known as: Losartan potassium

  • 100-mg losartan oral tablet + 50-mg losartan oral tablet

    Also known as: Losartan potassium

06

What researchers measure

Primary outcomes

  1. Number of Participants That Experienced One Component of the Composite Clinical Endpoint of All Cause Death or Hospitalization for Heart Failure

    Time frame: Entire follow-up (median = 4.7 years)

Secondary outcomes

  1. Number of Participants That Experienced One Components of the Composite Clinical Endpoint of All Cause Death or Cardiovascular Hospitalization

    Cardiovascular hospitalization is defined as any hospitalization that may be attributed to a cardiovascular cause, including heart failure.

    Time frame: Entire follow-up (median = 4.7 years)

  2. Number of Participants That Died (Any Cause)

    Time frame: Entire follow-up (median = 4.7 years)

  3. Number of Participants That Were Hospitalized for Heart Failure

    Time frame: Entire follow-up (median = 4.7 years)

  4. Number of Participants That Experienced Cardiovascular Hospitalization

    Time frame: Entire follow-up (median = 4.7 years)

07

Results

Posted Aug 2, 2010

Participant flow

First patient in: Nov-2001. Last patient out: May-2009. 255 sites in 30 countries participated (Peru , Chile, Columbia, Mexico, Brazil, Belgium, Croatia, France, Germany, Greece, Holland, Italy, Norway, Poland, Russia, Slovenia, Spain, Turkey, UK, Egypt, Lebanon, Morocco, S. Africa, China, Hong Kong, Korea, Malaysia, Philippines, Singapore, Taiwan)

Participant flow — Overall Study
MilestoneLosartan 50 mgLosartan 150 mg
Started19131921
Completed18511873
Not completed6248
Withdrew: Lost to follow-up3026
Withdrew: Withdrawal by subject2115
Withdrew: Investigator site closed117

Outcome measures

PrimaryNumber of Participants That Experienced One Component of the Composite Clinical Endpoint of All Cause Death or Hospitalization for Heart Failure
Time frame:
Entire follow-up (median = 4.7 years)
Reported as:
Number · Participants
Number of Participants That Experienced One Component of the Composite Clinical Endpoint of All Cause Death or Hospitalization for Heart Failure
ParticipantsLosartan 50 mgLosartan 150 mg
Number of Participants That Experienced One Component of the Composite Clinical Endpoint of All Cause Death or Hospitalization for Heart Failure889828
Statistical analysis
  • Losartan 50 mg vs Losartan 150 mg · Regression, Cox · p = 0.027 · Hazard ratio (hr): 0.899 · 95% CI 0.818 to 0.988Direction of the Comparison: Hazard Ratio of experiencing the endpoint on Losartan 150 mg compared to Losartan 50 mg
SecondaryNumber of Participants That Experienced One Components of the Composite Clinical Endpoint of All Cause Death or Cardiovascular Hospitalization

Cardiovascular hospitalization is defined as any hospitalization that may be attributed to a cardiovascular cause, including heart failure.

Time frame:
Entire follow-up (median = 4.7 years)
Reported as:
Number · Participants
Number of Participants That Experienced One Components of the Composite Clinical Endpoint of All Cause Death or Cardiovascular Hospitalization
ParticipantsLosartan 50 mgLosartan 150 mg
Number of Participants That Experienced One Components of the Composite Clinical Endpoint of All Cause Death or Cardiovascular Hospitalization10851037
Statistical analysis
  • Losartan 50 mg vs Losartan 150 mg · Regression, Cox · p = 0.068 · Hazard ratio (hr): 0.924 · 95% CI 0.848 to 1.006Direction of the Comparison: Hazard Ratio of experiencing the endpoint on Losartan 150 mg compared to Losartan 50 mg
SecondaryNumber of Participants That Died (Any Cause)
Time frame:
Entire follow-up (median = 4.7 years)
Reported as:
Number · Participants
Number of Participants That Died (Any Cause)
ParticipantsLosartan 50 mgLosartan 150 mg
Number of Participants That Died (Any Cause)665635
Statistical analysis
  • Losartan 50 mg vs Losartan 150 mg · Regression, Cox · p = 0.235 · Hazard ratio (hr): 0.936 · 95% CI 0.840 to 1.044Direction of the Comparison: Hazard Ratio of experiencing the endpoint on Losartan 150 mg compared to Losartan 50 mg
SecondaryNumber of Participants That Were Hospitalized for Heart Failure
Time frame:
Entire follow-up (median = 4.7 years)
Reported as:
Number · Participants
Number of Participants That Were Hospitalized for Heart Failure
ParticipantsLosartan 50 mgLosartan 150 mg
Number of Participants That Were Hospitalized for Heart Failure503450
Statistical analysis
  • Losartan 50 mg vs Losartan 150 mg · Regression, Cox · p = 0.025 · Hazard ratio (hr): 0.865 · 95% CI 0.762 to 0.982Direction of the Comparison: Hazard Ratio of experiencing the endpoint on Losartan 150 mg compared to Losartan 50 mg
SecondaryNumber of Participants That Experienced Cardiovascular Hospitalization
Time frame:
Entire follow-up (median = 4.7 years)
Reported as:
Number · Participants
Number of Participants That Experienced Cardiovascular Hospitalization
ParticipantsLosartan 50 mgLosartan 150 mg
Number of Participants That Experienced Cardiovascular Hospitalization826762
Statistical analysis
  • Losartan 50 mg vs Losartan 150 mg · Regression, Cox · p = 0.023 · Hazard ratio (hr): 0.892 · 95% CI 0.808 to 0.984Direction of the Comparison: Hazard Ratio of experiencing the endpoint on Losartan 150 mg compared to Losartan 50 mg

Adverse events

Collected over All adverse experiences that occurred during or up to 14 days after permanent or temporary discontinuation of the study treatment were included in the safety analyses. Per guidelines, endpoints were not reported as serious adverse experiences.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Losartan 50 mg—691/1,913 (36.1%)1,358/1,913 (71%)
Losartan 150 mg—710/1,921 (37%)1,394/1,921 (72.6%)
Most frequent serious events
Showing 10 of 786
Most frequent serious events
EventLosartan 50 mgLosartan 150 mg
PneumoniaInfections and infestations88/191372/1921
Renal failureRenal and urinary disorders33/191343/1921
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders26/191328/1921
AnaemiaBlood and lymphatic system disorders19/191324/1921
Renal failure acuteRenal and urinary disorders21/191321/1921
OsteoarthritisMusculoskeletal and connective tissue disorders15/191321/1921
SepsisInfections and infestations18/191320/1921
GastroenteritisInfections and infestations17/191319/1921
Inguinal herniaGastrointestinal disorders18/191311/1921
BronchitisInfections and infestations18/191312/1921
Most frequent other events
Showing 10 of 27
Most frequent other events
EventLosartan 50 mgLosartan 150 mg
Blood creatinine increasedGeneral disorders163/1913285/1921
DizzinessNervous system disorders254/1913245/1921
Cardiac failureCardiac disorders231/1913200/1921
BronchitisInfections and infestations231/1913222/1921
Blood urea increasedGeneral disorders159/1913222/1921
NasopharyngitisInfections and infestations170/1913195/1921
CoughRespiratory, thoracic and mediastinal disorders179/1913170/1921
HypotensionVascular disorders127/1913178/1921
Blood uric acid increasedGeneral disorders150/1913167/1921
DyspnoeaRespiratory, thoracic and mediastinal disorders166/1913152/1921

Baseline characteristics

Age, Continuous
Age, Continuous(years)Losartan 50 mgLosartan 150 mgTotal
Mean64.1 (19 to 95)64.4 (18 to 98)64.2 (18 to 98)
Age, Customized
Age, Customized(participants)Losartan 50 mgLosartan 150 mgTotal
< 65 years of Age8898791768
>=65 years of Age102410422066
Sex: Female, Male
Sex: Female, Male(Participants)Losartan 50 mgLosartan 150 mgTotal
Female5605831143
Male135313382691
Angiotensin II antagonists
Angiotensin II antagonists(Participants)Losartan 50 mgLosartan 150 mgTotal
No456438894
Yes145714832940
New York Heart Association (NYHA) functional status
New York Heart Association (NYHA) functional status(Participants)Losartan 50 mgLosartan 150 mgTotal
I No symptoms213
II Mild symptoms133013272657
III Marked limitation5695831152
IV Severe limitations121022
Region
Region(participants)Losartan 50 mgLosartan 150 mgTotal
Asia and Pacific Region391390781
East Europe212207419
Middle East and Africa9797194
Latin America309315624
West Europe9049121816
β - Blocker therapy
β - Blocker therapy(Participants)Losartan 50 mgLosartan 150 mgTotal
No5435331076
Yes137013882758
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Upshaw JN, Konstam MA, Klaveren Dv, Noubary F, Huggins GS, Kent DM. Multistate Model to Predict Heart Failure Hospitalizations and All-Cause Mortality in Outpatients With Heart Failure With Reduced Ejection Fraction: Model Derivation and External Validation. Circ Heart Fail. 2016 Aug;9(8):e003146. doi: 10.1161/CIRCHEARTFAILURE.116.003146. PubMed 27514751 ↗
  • Rossignol P, Girerd N, Gregory D, Massaro J, Konstam MA, Zannad F. Increased visit-to-visit blood pressure variability is associated with worse cardiovascular outcomes in low ejection fraction heart failure patients: Insights from the HEAAL study. Int J Cardiol. 2015;187:183-9. doi: 10.1016/j.ijcard.2015.03.169. Epub 2015 Mar 17. PubMed 25828348 ↗
  • Kiernan MS, Gregory D, Sarnak MJ, Rossignol P, Massaro J, Kociol R, Zannad F, Konstam MA. Early and late effects of high- versus low-dose angiotensin receptor blockade on renal function and outcomes in patients with chronic heart failure. JACC Heart Fail. 2015 Mar;3(3):214-23. doi: 10.1016/j.jchf.2014.11.004. Erratum In: JACC Heart Fail. 2015 Jun;3(6):510-1. PubMed 25742759 ↗
  • Konstam MA, Neaton JD, Dickstein K, Drexler H, Komajda M, Martinez FA, Riegger GA, Malbecq W, Smith RD, Guptha S, Poole-Wilson PA; HEAAL Investigators. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet. 2009 Nov 28;374(9704):1840-8. doi: 10.1016/S0140-6736(09)61913-9. Epub 2009 Nov 16. Erratum In: Lancet. 2009 Dec 5;374(9705):1888. PubMed 19922995 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2001 to primary completion in Mar 2009, 87 months.

Results were first posted in Aug 2010, 1 year 4 months after primary completion.

Of 63 industry-sponsored phase 3 interventional studies under Heart Failure, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 44. This study's 87 months is above that.

Counting every sponsor, half of 150 studies reached it within 39 months; a quarter within 26 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2004
First posted
Aug 27, 2004
StartActual
Dec 19, 2001
Primary completionActual
Mar 31, 2009
CompletionActual
May 13, 2009
Results first posted
Aug 2, 2010
Last update
May 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00090259
Lead sponsor
Organon and Co
Responsible party
Sponsor
First posted
Aug 27, 2004
Start date
Dec 19, 2001
Primary completion
Mar 31, 2009
Completion
May 13, 2009
Results posted
Aug 2, 2010
Last update
May 16, 2024

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Losartan

Start the discussion